Myoclonus and dystonia in cerebrotendinous xanthomatosis

Movement Disorders

Volumn 27, Issue 14, 2012, Pages 1805-1810

  Lagarde, Julien ^a   Roze, Emmanuel ^a   Apartis, Emmanuelle ^b   Pothalil, Deepa ^a,b   Sedel, Frédéric ^a   Couvert, Philippe ^a,c   Vidailhet, Marie ^a   Degos, Bertrand ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSERM   (France)

Author keywords

Cerebrotendinous xanthomatosis; Dentate nucleus; Dystonia; Myoclonus

Indexed keywords

ARTICLE; CEREBROTENDINOUS XANTHOMATOSIS; ELECTROPHYSIOLOGY; HUMAN; MYOCLONUS DYSTONIA; NEUROPHYSIOLOGY; NEURORADIOLOGY; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ADOLESCENT; AGE OF ONSET; COGNITION DISORDERS; DYSTONIA; EPILEPSY; FEMALE; HUMANS; MALE; MYOCLONUS; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 84871788085     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25206     Document Type: Article

References (37)

1. Federico A, Dotti MT. Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 2003; 18: 633-638.
2. Verrips A, Hoefsloot LH, Steenbergen GCH, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123: 908-919.
3. Roze E, Apartis E. Inherited myoclonus. In: Albanese A, Jankovic J, eds. Hyperkinetic Movement Disorders: Diagnosis Etiology And Treatment. Wiley-Blackwell Publishing; 2012: 209-220.
4. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008; 70: 1010-1016.
5. Obeso JA, Rothwell JC, Lang AE, Marsden CD. Myoclonic dystonia. Neurology 1983; 33: 825-830.
6. Grabli D, Auré K, Vidailhet M, Roze E. Movement disorders in neurometabolic diseases. In: Galvez-Jiménez N, Tuite PJ, eds. Uncommon Causes Of Movement Disorders. Cambridge University Press; 2011: 245-257.
7. Roze E, Paschke E, Lopez N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005; 20: 1366-1369.
8. Gitiaux C, Roze E, Kinugawa K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients. Mov Disord 2008; 23: 2392-2397.
9. Kuriyama M, Fujiyama J, Yoshidome H, et al. Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci 1991; 102: 225-232.
10. Grandas F, Martin-Moro M, Garcia-Munozguren S, Ananya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord 2002; 17: 1396-1397.
11. Dotti MT, Federico A, Garuti R, Calandra S. Cerebrotendinous xanthomatosis with predominant parkinsonian syndrome: further confirmation of the clinical heterogeneity. Mov Disord 2000; 15: 1017-1019.
12. Su CS, Chang WN, Huang SH, et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 2010; 25: 452-458.
13. Wakamatsu N, Hayashi M, Kawai H, et al. Mutations producing premature termination of translation and an aminoacid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J Neurol Neurosurg Psychiatry 1999; 67: 195-198.
14. Fiorelli M, Di Piero V, Bastianello S, Bozzao L, Federico A. Cerebrotendinous xanthomatosis: clinical and MRI study (a case report). J Neurol Neurosurg Psychiatry 1990; 53: 76-78.
15. Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci 2001; 182: 95-97.
16. Kuwabara K, Hitoshi S, Nukina N, et al. PET analysis of a case of cerebrotendinous xanthomatosis presenting hemiparkinsonism. J Neurol Sci 1996; 138: 145-149.
17. Fujiyama J, Kuriyama M, Yoshidome H, et al. Parkinsonism in cerebrotendinous xanthomatosis. Jpn J Med 1991; 30: 189-192.
18. Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A. Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 2008; 255: 839-842.
19. Verrips A, van Engelen BGM, Wevers RA, et al. Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol 2000; 57: 520-524.
20. Rogelet P, Gérard JM, Michotte A, Masingue M, Destée A. Cerebrotendinous xanthomatosis. 2 cases with magnetic resonance imaging. Rev Neurol (Paris) 1992; 148: 541-545.
21. Bavinck JNB, Vermeer BJ, Gevers Leuven JA, Koopman BJ, Wolthers BG. Capillary gas chromatography of urine samples in diagnosing cerebrotendinous xanthomatosis. Arch Dermatol 1986; 122: 1269-1272.
22. Mignarri A, Falcini M, Vella A, et al. Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2012; 18: 99-101.
23. Rubio-Agusti I, Kojovic M, Edwards MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and literature review. Mov Disord 2012 (In Press).
24. Donaghy M, King RH, McKeran RO, Schwartz MS, Thomas PK. Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodesoxycholic acid. J Neurol 1990; 237: 216-219.
25. Szlago M, Gallus GN, Schenone A, et al. The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology 2008; 70: 402-404.
26. Philippart M, van Bogaert M. Cholestanolosis (cerebrotendinous xanthomatosis): a follow-up study on the original family. Arch Neurol 1969; 21: 603-610.
27. Isenhardt K, Schmitt R, Nagel A, Drach L, Schlote W. Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study. Clin Neuropathol 2005; 24: 276-283.
28. Alcalay RN, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord 2009; 24: 1397-1399.
29. Bordia S, Saifee AA. Cerebrotendinous xanthomatosis with oromandibular dyskinesia. Neurol India 2003; 51: 556-558.
30. Posada IJ, Ramos A. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2011; 17: 570-572.
31. Trustwell AS, Pfister PJVS. Cerebrotendinous xanthomatosis. Br Med J 1972; 1: 353-354.
32. Brodsky JW, Beischer AD, East C, et al. Cerebrotendinous xanthomatosis: a rare cause of bilateral Achilles tendon swelling and ataxia. J Bone Joint Surg Am 2006; 88: 1340-1344.
33. Shaikh AG, Hong S, Liao K, et al. Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticity. Brain 2010; 133: 923-940.
34. Hoshi E, Tremblay L, Féger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci 2005; 8: 1491-1493.
35. Neychev VK, Fan X, Mitev VI, Hess EJ, Jinnah HA. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 2008; 131: 2499-2509.
36. Ritz K, van Schaik BD, Jakobs ME, et al. SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet 2011; 19: 438-444.
37. Beukers RJ, Foncke EM, van der Meer JN, et al. Disorganized sensorimotor integration in mutation-positive myoclonus-dystonia: a functional magnetic resonance imaging study. Arch Neurol 2010; 67: 469-474.